Inhibition of hypertrophy and improving chondrocyte differentiation by MMP-13 inhibitor small molecule encapsulated in alginate-chondroitin sulfate-platelet lysate hydrogel.
And mechanical properties
Chondrocyte hypertrophy
MMP-13 inhibitor
Platelet lysate
Small molecules
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
09 10 2020
09 10 2020
Historique:
received:
04
03
2020
accepted:
08
09
2020
entrez:
10
10
2020
pubmed:
11
10
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Mesenchymal stem cells are a promising cell source for chondrogenic differentiation and have been widely used in several preclinical and clinical studies. However, they are prone to an unwanted differentiation process towards hypertrophy that limits their therapeutic efficacy. Matrix metallopeptidase 13 (MMP-13) is a well-known factor regulated during this undesirable event. MMP-13 is a collagen degrading enzyme, which is also highly expressed in the hypertrophic zone of the growth plate and in OA cartilage. Accordingly, we investigated the effect of MMP-13 inhibition on MSC hypertrophy. In this study, 5-bromoindole-2-carboxylic acid (BICA) was used as an inhibitory agent for MMP-13 expression. After identifying its optimal concentration, BICA was mixed into a hydrogel and the release rate was studied. To prepare the ideal hydrogel, chondroitin sulfate (CS) and platelet lysate (PL) were mixed with sodium alginate (Alg) at concentrations selected based on synergistic mechanical and rheometric properties. Then, four hydrogels were prepared by combining alginate (1.5%w/v) and/or CS (1%w/v) and/or PL (20%v/v). The chondrogenic potential and progression to hypertrophy of human bone marrow-derived mesenchymal stem cell (hBM-MSC)-loaded hydrogels were investigated under free swelling and mechanical loading conditions, in the presence and absence of BICA. Viability of hBM-MSCs seeded in the four hydrogels was similar. qRT-PCR revealed that BICA could successfully inhibit MMP-13 expression, which led to an inhibition of Coll X and induction of Coll-II, in both free swelling and loading conditions. The GAG deposition was higher in the group combining BICA and mechanical stimulation. It is concluded that BICA inhibition of MMP-13 reduces MSC hypertrophy during chondrogenesis.
Sections du résumé
BACKGROUND
Mesenchymal stem cells are a promising cell source for chondrogenic differentiation and have been widely used in several preclinical and clinical studies. However, they are prone to an unwanted differentiation process towards hypertrophy that limits their therapeutic efficacy. Matrix metallopeptidase 13 (MMP-13) is a well-known factor regulated during this undesirable event. MMP-13 is a collagen degrading enzyme, which is also highly expressed in the hypertrophic zone of the growth plate and in OA cartilage. Accordingly, we investigated the effect of MMP-13 inhibition on MSC hypertrophy.
METHODS
In this study, 5-bromoindole-2-carboxylic acid (BICA) was used as an inhibitory agent for MMP-13 expression. After identifying its optimal concentration, BICA was mixed into a hydrogel and the release rate was studied. To prepare the ideal hydrogel, chondroitin sulfate (CS) and platelet lysate (PL) were mixed with sodium alginate (Alg) at concentrations selected based on synergistic mechanical and rheometric properties. Then, four hydrogels were prepared by combining alginate (1.5%w/v) and/or CS (1%w/v) and/or PL (20%v/v). The chondrogenic potential and progression to hypertrophy of human bone marrow-derived mesenchymal stem cell (hBM-MSC)-loaded hydrogels were investigated under free swelling and mechanical loading conditions, in the presence and absence of BICA.
RESULTS
Viability of hBM-MSCs seeded in the four hydrogels was similar. qRT-PCR revealed that BICA could successfully inhibit MMP-13 expression, which led to an inhibition of Coll X and induction of Coll-II, in both free swelling and loading conditions. The GAG deposition was higher in the group combining BICA and mechanical stimulation.
CONCLUSIONS
It is concluded that BICA inhibition of MMP-13 reduces MSC hypertrophy during chondrogenesis.
Identifiants
pubmed: 33036643
doi: 10.1186/s13287-020-01930-1
pii: 10.1186/s13287-020-01930-1
pmc: PMC7545577
doi:
Substances chimiques
Alginates
0
Hydrogels
0
Matrix Metalloproteinase Inhibitors
0
Chondroitin Sulfates
9007-28-7
Matrix Metalloproteinase 13
EC 3.4.24.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
436Références
Exp Cell Res. 1998 Jan 10;238(1):265-72
pubmed: 9457080
Biomaterials. 2012 May;33(14):3651-61
pubmed: 22349290
J Bone Joint Surg Br. 2009 May;91(5):565-76
pubmed: 19407287
Int J Biol Macromol. 2013 Oct;61:175-81
pubmed: 23817101
Osteoarthritis Cartilage. 2016 May;24(5):932-41
pubmed: 26774733
Interface Focus. 2014 Apr 6;4(2):20130038
pubmed: 24748951
Acta Biomater. 2013 May;9(5):6630-40
pubmed: 23403167
Acta Biomater. 2019 Jan 1;83:233-244
pubmed: 30366137
Clin Orthop Relat Res. 2011 Oct;469(10):2764-72
pubmed: 21344272
Matrix Biol. 2008 Jan;27(1):12-21
pubmed: 17689060
J Mech Behav Biomed Mater. 2009 Oct;2(5):512-21
pubmed: 19627858
Bone Res. 2017 May 30;5:17014
pubmed: 28584674
Invest Radiol. 2000 Oct;35(10):573-80
pubmed: 11041151
Tissue Eng Part A. 2008 May;14(5):667-80
pubmed: 18377198
Biomacromolecules. 2010 Dec 13;11(12):3228-36
pubmed: 21105638
Eur J Cell Biol. 2000 Sep;79(9):601-9
pubmed: 11043401
J Med Chem. 2011 Dec 8;54(23):8174-87
pubmed: 22017539
Osteoarthritis Cartilage. 2014 Jan;22(1):145-53
pubmed: 24269634
Int J Biol Macromol. 2018 Feb;107(Pt B):2686-2694
pubmed: 29101050
J Cell Sci. 2017 Jan 1;130(1):51-61
pubmed: 27856508
Mol Cancer Ther. 2018 Jun;17(6):1147-1155
pubmed: 29735645
J Tissue Eng Regen Med. 2015 Jul;9(7):808-18
pubmed: 23303715
J Biomed Mater Res A. 2005 Nov 1;75(2):485-93
pubmed: 16092113
Carbohydr Polym. 2018 Apr 15;186:377-383
pubmed: 29456000
J Biomed Mater Res A. 2014 Dec;102(12):4519-25
pubmed: 24677739
Int J Biol Macromol. 2017 Feb;95:962-973
pubmed: 27793679
Curr Med Chem. 2011;18(7):977-1001
pubmed: 21254976
Expert Opin Drug Deliv. 2015 Apr;12(4):525-45
pubmed: 25297510
J Neurosci Res. 2011 Feb;89(2):117-26
pubmed: 21162120
Int J Biol Macromol. 2018 Jul 1;113:132-141
pubmed: 29452185
Trends Cell Biol. 2018 Dec;28(12):1014-1029
pubmed: 30361056
Carbohydr Polym. 2017 Apr 15;162:100-107
pubmed: 28224886
Arthritis Res Ther. 2017 Nov 10;19(1):248
pubmed: 29126436
Biomaterials. 2007 Feb;28(6):1071-83
pubmed: 17123602
Osteoarthritis Cartilage. 2006 Oct;14(10):1023-32
pubmed: 16731008
Curr Drug Discov Technol. 2008 Dec;5(4):289-301
pubmed: 19075609
Biomaterials. 2019 Jan;190-191:51-62
pubmed: 30391802
J Mater Sci Mater Med. 2018 Jun 14;29(6):88
pubmed: 29904797
Osteoarthritis Cartilage. 2004 Dec;12(12):963-73
pubmed: 15564063
Biomaterials. 2011 Feb;32(5):1327-38
pubmed: 21067807
Tissue Eng Part A. 2013 Jun;19(11-12):1349-59
pubmed: 23379843
Tissue Eng Part A. 2010 Jun;16(6):1845-55
pubmed: 20067399
Arthritis Rheum. 2009 Apr;60(4):1035-41
pubmed: 19333945
J Cell Biochem. 2000 Apr;77(4):678-93
pubmed: 10771523
Bone Miner. 1991 Nov;15(2):151-63
pubmed: 1764631
Materials (Basel). 2013 Mar 26;6(4):1285-1309
pubmed: 28809210
Instr Course Lect. 1998;47:487-504
pubmed: 9571450
Tissue Eng. 1999 Dec;5(6):545-54
pubmed: 10611546
J Tissue Eng Regen Med. 2017 Oct;11(10):2876-2884
pubmed: 27339032
Cell Mol Biol Lett. 2018 Mar 20;23:11
pubmed: 29568314
Integr Biol (Camb). 2015 Jan;7(1):112-27
pubmed: 25387395
Biomacromolecules. 2016 Jun 13;17(6):1985-97
pubmed: 27203709
Carbohydr Polym. 2019 Feb 15;206:229-237
pubmed: 30553317
Calcif Tissue Int. 2000 Sep;67(3):230-40
pubmed: 10954778
Carbohydr Polym. 2016 Nov 20;153:34-46
pubmed: 27561469
Science. 1999 Apr 2;284(5411):143-7
pubmed: 10102814
Acta Biomater. 2016 May;36:86-98
pubmed: 26961805
Birth Defects Res C Embryo Today. 2010 Mar;90(1):75-85
pubmed: 20301221
Tissue Eng Part A. 2013 Jun;19(11-12):1285-94
pubmed: 23289669
Cell Tissue Res. 2012 Mar;347(3):613-27
pubmed: 22030892
Biomacromolecules. 2008 Sep;9(9):2562-6
pubmed: 18680341
Biofabrication. 2016 Jul 19;8(3):035002
pubmed: 27431574
Biomaterials. 2007 Apr;28(12):2077-86
pubmed: 17257670
Methods Mol Biol. 2015;1340:41-52
pubmed: 26445829
Carbohydr Polym. 2018 Jan 1;179:186-195
pubmed: 29111041
Osteoarthritis Cartilage. 2007 Oct;15(10):1178-89
pubmed: 17502159
Biochem Biophys Res Commun. 2014 Sep 26;452(3):526-30
pubmed: 25172660
Osteoarthritis Cartilage. 2006 Feb;14(2):179-89
pubmed: 16257243
Curr Top Dev Biol. 2004;60:91-126
pubmed: 15094297
Acta Biomater. 2014 Aug;10(8):3650-63
pubmed: 24811827
Osteoarthritis Cartilage. 2012 Mar;20(3):223-32
pubmed: 22178514
Biopolymers. 2008 Oct;89(10):841-51
pubmed: 18488988
Drug Deliv. 2018 Nov;25(1):1438-1447
pubmed: 29890922
Biomaterials. 2010 Jan;31(2):270-8
pubmed: 19783038
J Cell Mol Med. 2010 Jun;14(6A):1338-46
pubmed: 19432813
Acta Biomater. 2018 Mar 1;68:29-40
pubmed: 29341933
Tissue Eng. 2004 Sep-Oct;10(9-10):1436-45
pubmed: 15588403
J Biomater Sci Polym Ed. 2004;15(9):1223-36
pubmed: 15503636
J Biomed Mater Res B Appl Biomater. 2018 Oct;106(7):2576-2587
pubmed: 29331090
Nucleic Acids Res. 2001 Nov 1;29(21):4361-72
pubmed: 11691923
J Funct Biomater. 2014 Sep 18;5(3):197-210
pubmed: 25238548
Arthritis Res Ther. 2011;13(6):R203
pubmed: 22151902
Arthritis Res. 2002;4(3):157-64
pubmed: 12010565
J Tissue Eng Regen Med. 2018 Mar;12(3):e1691-e1703
pubmed: 29052350
Tissue Eng Part A. 2011 Feb;17(3-4):371-80
pubmed: 20799905
Biomaterials. 2018 Feb;156:16-27
pubmed: 29182933
Cytotherapy. 2013 Dec;15(12):1469-83
pubmed: 23981539
J Biomed Mater Res A. 2008 Mar 15;84(4):899-907
pubmed: 17647237
Eur J Pharm Sci. 2018 Jun 15;118:87-95
pubmed: 29574078
Mater Sci Eng C Mater Biol Appl. 2015 May;50:160-72
pubmed: 25746258
J Biol Chem. 2001 Apr 6;276(14):11347-53
pubmed: 11145962
Carbohydr Polym. 2016 Aug 20;147:294-303
pubmed: 27178935
Instr Course Lect. 1998;47:477-86
pubmed: 9571449